Search results for "heart Failure"

showing 10 items of 863 documents

The relationship between age and production of tumour necrosis factor-α in healthy volunteers and patients with chronic heart failure

2003

Ageing is associated with an altered immune response. Elevated plasma levels of tumour necrosis factor-alpha (TNF-alpha) are present in patients with advanced chronic heart failure (CHF). However, the relationship between age and the immune response in CHF is unknown.We investigated the relationship between age and the TNF-alpha generating capacity of lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in nine healthy control subjects (mean age 51.6+/-3.6 years, age range 39-75 years) and 22 stable patients with CHF (mean age 68.3+/-1.5 years, age range 52-78 years, NYHA class 3.0+/-0.2). We also tested the TNF-alpha generating capacity of all control subjects and …

AdultLipopolysaccharidesMalemedicine.medical_specialtyHeart diseaseEnzyme-Linked Immunosorbent AssayPeripheral blood mononuclear cellMonocytesImmune systemInternal medicinemedicineHumansAgedWhole bloodHeart FailureAnalysis of VarianceTumor Necrosis Factor-alphabusiness.industryAge FactorsGestational ageMiddle Agedmedicine.diseaseLogistic ModelsEndocrinologyAgeingCase-Control StudiesHeart failureChronic DiseaseImmunologyFemaleTumor necrosis factor alphaCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct

Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chro…

2005

Increased levels of tumor necrosis factor-alpha (TNF-alpha) correlate with poor prognoses in chronic heart failure (CHF). This study demonstrated that noradrenaline and isoproterenol inhibit TNF-alpha production in patients with CHF in ex vivo whole blood in a dose-dependent fashion. The beta-blocker bisoprolol abolishes this effect.

AdultLipopolysaccharidesMalemedicine.medical_specialtyLipopolysaccharideAdrenergic receptorAdrenergic beta-AntagonistsNorepinephrinechemistry.chemical_compoundInternal medicineReceptors Adrenergic betamedicineBisoprololHumansReceptorWhole bloodHeart FailureTumor Necrosis Factor-alphabusiness.industryIsoproterenolCardiovascular Agentsmedicine.diseaseEndocrinologychemistryBisoprololHeart failurecardiovascular systemCardiologyFemaleTumor necrosis factor alphaCardiology and Cardiovascular MedicinebusinessEx vivomedicine.drugThe American Journal of Cardiology
researchProduct

Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunc…

2015

Abstract Background Cirrhotic cardiomyopathy may lead to heart failure in stressful circumstances, such as after transjugular intrahepatic portosystemic shunt (TIPS) placement. Aim To examine whether acute volume expansion predicts haemodynamic changes after TIPS and elicits signs of impending heart failure. Methods We prospectively evaluated refractory ascites patients (group A) and compensated cirrhotics (group B), who underwent echocardiography, NT-proBNP measurement, and heart catheterization before and after volume load; group A repeated measurements after TIPS. Results 15 patients in group A (80% male; 54 ± 12.4 years) and 8 in group B (100% male; 56 ± 6.2 years) were enrolled. Echoca…

AdultLiver CirrhosisMaleCardiac Catheterizationmedicine.medical_specialtymedicine.medical_treatmentCardiac indexDiastoleElectrocardiographyInternal medicineNatriuretic Peptide BrainmedicineHumansProspective StudiesPulmonary wedge pressureAgedCardiac catheterizationHeart Failure DiastolicHepatologybusiness.industryHemodynamicsGastroenterologyAscitesMiddle Agedmedicine.diseasePeptide Fragmentsmedicine.anatomical_structureEchocardiographySpainHeart failureHeart catheterizationVascular resistanceCardiologyFemaleVascular ResistancePortasystemic Shunt Transjugular IntrahepaticbusinessTransjugular intrahepatic portosystemic shuntDigestive and Liver Disease
researchProduct

Does angiotensin-converting enzyme gene polymorphism affect blood pressure? Findings after 6 years of follow-up in healthy subjects.

2003

Background: There has been an increase in research into the association between angiotensin-converting enzyme (ACE) gene deletion polymorphism and cardiovascular disease, with conflicting results. The present prospective long-term study was conducted to evaluate whether the DD genotype could also be associated with a higher prevalence of hypertension in healthy subjects, over 6 years of follow-up. Methods: Population: 684 healthy volunteers (aged, 25–55 years): normotensive and free of cardiovascular diseases, with acceptable echocardiographic window. All subjects had to have a normal electrocardiogram (ECG) and echocardiogram (ECHO) at entry. Study protocol: All subjects underwent a comple…

AdultMaleACE-I/D gene polymorphismmedicine.medical_specialtyTime FactorsGenotypePopulationBlood PressurePeptidyl-Dipeptidase AReference ValuesInternal medicineMedicineHumansProspective StudiesFamily historyeducationeducation.field_of_studyPolymorphism Geneticbiologybusiness.industryIncidence (epidemiology)IncidenceAngiotensin-converting enzymeVenous bloodMiddle Agedmedicine.diseaseMutagenesis InsertionalEndocrinologyBlood pressureHeart failureHypertensionbiology.proteinFemaleGene polymorphismCardiology and Cardiovascular MedicinebusinessHealthy subjectGene DeletionFollow-Up StudiesEuropean journal of heart failure
researchProduct

Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study

2021

Background Thrombosis and pulmonary embolism appear to be major causes of mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have focused on the incidence of venous thromboembolism (VTE) after hospitalization for COVID-19. Methods In this multi-center study, we followed 1529 COVID-19 patients for at least 45 days after hospital discharge, who underwent routine telephone follow-up. In case of signs or symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT), they were invited for an in-hospital visit with a pulmonologist. The primary outcome was symptomatic VTE within 45 days of hospital discharge. Results Of 1529 COVID-19 patients discharge…

AdultMaleARDSmedicine.medical_specialtyTime FactorsDeep veinIran030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsFull Length ArticleInternal medicinemedicineHumansProspective Studiescardiovascular diseasesMyocardial infarctionThromboprophylaxisStrokeAgedAged 80 and overVenous Thrombosisbusiness.industryIncidenceIncidence (epidemiology)COVID-19Venous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisPatient DischargePulmonary embolismHospitalizationmedicine.anatomical_structure030220 oncology & carcinogenesisHeart failureFemaleCohort studyPulmonary EmbolismbusinessThrombosis Research
researchProduct

Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial fu…

2010

Endothelium-dependent flow-mediated dilation (FMD) is measured as the increase in diameter of a conduit artery in response to reactive hyperemia, assessed either at a fixed time point [usually 60-s post-cuff deflation (FMD60)] or as the maximal dilation during a 5-min continuous, ECG-gated, measurement (FMDmax-cont). Preliminary evidence suggests that the time between reactive hyperemia and peak dilation (time to FMDmax) may provide an additional index of endothelial health. We measured FMDmax-cont, FMD60, and time to FMDmax in 30 young healthy volunteers, 22 healthy middle-aged adults, 16 smokers, 23 patients with hypertension, 40 patients with coronary artery disease, and 22 patients wit…

AdultMaleAdolescentBrachial ArteryEndotheliumPhysiologyCoronary Artery DiseaseElectrical conduitForearmPhysiology (medical)medicineHumanscardiovascular diseasesEnzyme InhibitorsReactive hyperemiaHeart FailureAnalysis of Variancebusiness.industrySmokingMiddle AgedVasodilationNG-Nitroarginine Methyl Estermedicine.anatomical_structureRegional Blood FlowAnesthesiaHypertensionCirculatory systemcardiovascular systemDilation (morphology)FemaleEndothelium VascularCardiology and Cardiovascular MedicinebusinessBlood vesselArteryAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Role of Circulating miRNAs as Biomarkers in Idiopathic Pulmonary Arterial Hypertension: Possible Relevance of miR-23a

2015

Idiopathic pulmonary hypertension (IPAH) is a rare disease characterized by a progressive increase in pulmonary vascular resistance leading to heart failure. MicroRNAs (miRNAs) are small noncoding RNAs that control the expression of genes, including some involved in the progression of IPAH, as studied in animals and lung tissue. These molecules circulate freely in the blood and their expression is associated with the progression of different vascular pathologies. Here, we studied the expression profile of circulating miRNAs in 12 well-characterized IPAH patients using microarrays. We found significant changes in 61 miRNAs, of which the expression of miR23a was correlated with the patients’ …

AdultMaleAgingArticle SubjectNF-E2-Related Factor 2Idiopathic Pulmonary HypertensionBiologyBiochemistryPulmonary function testingmicroRNAmedicineGene silencingHumansFamilial Primary Pulmonary Hypertensionlcsh:QH573-671Cells CulturedAgedlcsh:CytologySuperoxide DismutaseGene Expression ProfilingCytochromes cCell BiologyGeneral MedicineMiddle Agedmedicine.diseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaGene expression profilingMicroRNAsmedicine.anatomical_structureHeart failureImmunologyVascular resistanceBiomarker (medicine)FemaleBiomarkersHeme Oxygenase-1Research ArticleTranscription FactorsOxidative Medicine and Cellular Longevity
researchProduct

PGC-1α Induction in Pulmonary Arterial Hypertension

2012

Idiopathic Pulmonary arterial hypertension (IPAH) is characterized by the obstructive remodelling of pulmonary arteries, and a progressive elevation in pulmonary arterial pressure (PAP) with subsequent right-sided heart failure and dead. Hypoxia induces the expression of peroxisome proliferator activated receptorγcoactivator-1α(PGC-1α) which regulates oxidative metabolism and mitochondrial biogenesis. We have analysed the expression of PGC-1α, cytochrome C (CYTC), superoxide dismutase (SOD), the total antioxidant status (TAS) and the activity of glutathione peroxidase (GPX) in blood samples of IPAH patients. Expression of PGC-1αwas detected in IPAH patients but not in healthy volunteers. Th…

AdultMaleAgingmedicine.medical_specialtyArticle SubjectHypertension PulmonaryPeroxisome proliferator-activated receptorBiologyBiochemistrySuperoxide dismutaseChloridesInternal medicinemedicineHumansFamilial Primary Pulmonary Hypertensionlcsh:QH573-671Heat-Shock ProteinsAgedchemistry.chemical_classificationGlutathione Peroxidaselcsh:CytologySuperoxide DismutaseGlutathione peroxidaseAge FactorsCytochromes cCell BiologyGeneral MedicineHypoxia (medical)Middle Agedmedicine.diseasePulmonary hypertensionPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaEndocrinologymedicine.anatomical_structurechemistryMitochondrial biogenesisHeart failurebiology.proteinVascular resistanceFemaleVascular Resistancemedicine.symptomTranscription FactorsResearch ArticleOxidative Medicine and Cellular Longevity
researchProduct

Manifestation and ultrastructural typing of amyloid deposits in the heart

1983

Using light and electron microscopy, 65 cases of amyloid deposits in the heart were examined. Five different groups were distinguished: I. isolated atrial amyloidosis, II. senile cardiac amyloidosis, III. cardiac amyloid accompanying chronic infections and tumors, IV. cardiac amyloid accompanying plasma cell dyscrasia, V. idiopathic cardiac amyloidosis. Seen structurally, no principal differences in the precise localization of the amyloid deposits were found in any of the groups investigated. Amyloid is always deposited in the vicinity of cells with myocytic cell differentiation (i.e. the heart muscle cells, non-striated muscle cells of the vessels), whereby the relevant basement membranes …

AdultMaleAmyloidPathologymedicine.medical_specialtyHistologyAdolescentAmyloidHeart diseasePlasma cell dyscrasiaAutopsyBasement MembranePathology and Forensic Medicinemental disordersmedicineHumansIsolated atrial amyloidosisHeart AtriaMolecular BiologyAgedbusiness.industryMyocardiumAmyloidosisCell DifferentiationAmyloidosisCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseCoronary VesselsMicroscopy ElectronCardiac amyloidosisHeart failurecardiovascular systemFemaleAnatomyCardiomyopathiesbusinessVirchows Archiv A Pathological Anatomy and Histopathology
researchProduct

The use of esmolol in whole-body hyperthermia: Cardiovascular effects

1997

Whole-body hyperthermia (WBH) is a well-described investigational adjunct to systemic chemotherapy for the treatment of advanced malignancies. The hemodynamic consequences of this physiologic state may include tachycardia, which can produce acute myocardial ischemia in patients with coronary artery disease. Ischemic heart disease is currently considered a contraindication to WBH. We chose to investigate the consequences of using a new beta 1-adrenergic antagonist, esmolol, to attempt to control the tachycardia associated with WBH. After institutional approval and patient consent, nine consecutive patients with normal cardiac function presenting for WBH with carboplatin infusion were studied…

AdultMaleCancer ResearchMean arterial pressureCardiac outputHeart diseasePhysiologySinus tachycardiaAdrenergic beta-AntagonistsCardiac indexAntineoplastic AgentsCoronary DiseaseCarboplatinPropanolaminesHeart RateNeoplasmsTachycardiaPhysiology (medical)Heart rateHumansMedicineInfusions Intravenousbusiness.industryContraindicationsHemodynamicsHyperthermia InducedMiddle Agedmedicine.diseaseEsmololCombined Modality TherapyAnesthesiaHeart failureFemaleSafetymedicine.symptombusinessmedicine.drugInternational Journal of Hyperthermia
researchProduct